Patent · US Expired

P53 protein variants and therapeutic uses thereof

US6326464A · kind A · utility

6Cited by

1References

11Claims

0Family size

Assignee

AVENTIS PHARMA S.A. · FR

Inventors

Emmanuel Conseiller · Paris, FR
Laurent Bracco · Paris, FR

Key dates

Filing date	Feb 20, 1998
Grant date	Dec 4, 2001
Priority date	—
Expiry date	Feb 20, 2018

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/828
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Proteins derived from the product of tumor suppressor gene p53 and having enhanced functions for therapeutical use are disclosed. The proteins advantageously have enhanced tumour suppressor and programmed cell death inducer functions, particularly in proliferative disease contexts where wild-type p53 protein is inactivated. Nucleic acids coding for such molecules, vectors containing same, and therapeutical use thereof, particularly in gene therapy, are also disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.